Indications for: LEQVIO

Adjunct to diet and statin therapy in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.

Adult Dosage:

Give by SC inj into abdomen, thigh, or upper arm. Initially 284mg as a single inj, repeat at 3 months, and then every 6 months. Measure LDL-lowering effect as early as 30 days after initiation and anytime thereafter.

Children Dosage:

Not established.

LEQVIO Warnings/Precautions:

Do not inject into areas of active skin disease or injury (eg, sunburns, skin rashes, inflammation, skin infections). ESRD. Severe hepatic impairment. Pregnancy: avoid. Nursing mothers.

LEQVIO Classification:

Small interfering RNA (siRNA).

Adverse Reactions:

Inj site reaction, arthralgia, bronchitis.


Primarily by nucleases. 

Drug Elimination:

Renal (~16%). Half-life: ~9 hours.

Generic Drug Availability:


How Supplied:

Single-dose prefilled syringe—1